T2D duration >12 years; insulin treatment; cardiovascular diseases (e.g., CAD, stroke, peripheral artery disease, heart failure); weight loss >5 kg in 6 months; inability to exercise; participants currently being treated with more than three glucose-lowering medications. This evidence concerns the gene INS and stroke disorder.